The ISCT is a global society of clinicians, regulators, technologists and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients’ lives. The scientific program includes symposia, educational sessions and workshops covering the key issues relating to cell therapy. Read more on www.isct2016.com
Kiadis Pharma has four abstracts that have been accepted for presentation at the International Society for Cellular Therapy (ISCT) 2016 Annual Meeting on May 25-28, 2016 in Singapore.
In addition, Jurjen Velthuis, the Company’s Vice-President CMC, gave a presentation on ‘Defining critical process parameters’ during the Session “Quality and Operations Track 5 – CMC Process Characterization and Parameters”.
See below the abstract of the oral presentation and the abstracts of the three poster presentations (including the posters):
“Phase II clinical trial of Allodepleted T-cell Immunotherapy (ATIR101) post-transplant results in decreased transplantrelated mortality and improved survival in acute leukemia patients undergoing T-depleted haploidentical stem cell transplantation”. See Abstract.
“Selective depletion of alloreactive T-cells while retaining virus-specific and memory T-cells from haploidentical donor lymphocytes”. See Abstract and Poster (P188).
“Leukemia-associated antigen reactive T-cells in ATIR101, a recipient-specific allodepleted T-cell product t0 reduce relapse rates and GVHD after haplo-HSCT”. See Abstract and Poster (P189).
“Application of Quality by Design in allogeneic cell-based therapy processes and assay development”. See Abstract and Poster (P238).
28, May, 2016,